TREM2 and Alzheimer disease: The nanomodulator can efficiently cross the BBB and co-deliver immunosuppressant TREM2-lowing antisense oligonucleotides and resveratrol towards M1 phenotype microglia, finally synergistically inhibiting chronically activated microglia for AD management.